What Is Follistatin? Benefits, Research & Safety
A natural glycoprotein that inhibits myostatin and activins, researched for muscle growth and metabolic effects.
UK summary: Not a licensed UK medicine. Myostatin inhibitor with research interest in muscular dystrophy and other muscle-wasting conditions. Prohibited at all times under WADA S1.2 (other anabolic agents). Some commercial preparations are gene-therapy constructs, not peptides — verify what's actually being sold.
Quick Facts
Overview
Follistatin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Myostatin inhibitor with research interest in muscular dystrophy and other muscle-wasting conditions. Prohibited at all times under WADA S1.2 (other anabolic agents). Some commercial preparations are gene-therapy constructs, not peptides — verify what's actually being sold.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed. Research compound only.
- EU: Not approved for any indication.
- Notes: Follistatin is not approved for muscle enhancement anywhere. Gene therapy approaches are in clinical trials for muscular dystrophies. It is prohibited by WADA. Products sold outside research settings have uncertain quality and authenticity.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Doubles muscle mass by inhibiting myostatin.
- Treats muscular dystrophy at home.
- Safe injectable peptide for bodybuilders.
- Undetectable in drug tests.
07Common internet claims
- Marketed in bodybuilding stacks as the ultimate myostatin inhibitor.
- Sold by online retailers as research-only peptide (often mis-described — some products are gene-therapy constructs, not the protein).
- Promoted via 'follistatin gene therapy' clinics overseas.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Builds muscle without steroids or HGH” | D | Limited | High | Animal-model evidence shows myostatin-inhibition muscle effects; human-outcomes evidence in healthy adults is limited and clinical use is research-only. |
| “Safe alternative to anabolic agents” | E | No | High | Prohibited under WADA S1.2 as an 'other anabolic agent'; safety profile in healthy adults is not established. |
| “Available as injection peptide from research suppliers” | E | No | High | Some 'follistatin' products on the grey market are mis-described or are gene-therapy constructs. Identity and purity unverified. |
| “Treats muscle-wasting conditions” | D | Limited | High | Clinical research is ongoing; no licensed UK follistatin medicine exists. |
09Safety uncertainty score
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Theoretical reproductive disruption (follistatin antagonises activin in HPG axis).
- Theoretical tendon weakness with disproportionate muscle growth.
- Unknown chronic effects of sustained myostatin suppression.
- Gene-therapy versions carry serious vector-related risks (immune response, integration).
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed. Research compound only.
14EU legal position
Not approved for any indication.
15What this page cannot tell you
- Whether a UK-purchased 'follistatin' product contains the protein or is something else entirely.
- Long-term consequences of myostatin pathway suppression in humans.
- Whether tendons and connective tissue can match the rate of muscle growth produced.
- WADA detection windows — assume detection, strict-liability applies.
16Last reviewed
17Citation quality score
18Research gaps
- Phase 2 / 3 trials in muscular dystrophy underway but no licensed product.
- Healthy-adult muscle-building outcome data absent.
- Long-term safety entirely unstudied.
- Gene-therapy follistatin trials are early-stage with significant safety questions.
19Safer alternatives / established care pathways
- Progressive resistance training with adequate protein — the only evidence-based muscle-growth intervention.
- Neuromuscular-disease specialist referral for genuine muscle-wasting conditions; licensed treatments exist for some.
- Endocrinology / sports medicine review for atypical muscle weakness.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Follistatin a licensed UK medicine?
- Are there UK clinical trials for the muscle condition I'm asking about?
- What licensed treatments exist for muscle wasting in my situation?
- If I'm an athlete, what is the WADA position?
- If a clinic is offering 'follistatin', what is it actually selling — peptide or gene therapy?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant muscle hypertrophy in animal and gene therapy studies
- 2Potential treatment for muscular dystrophies
- 3May counteract age-related muscle loss (sarcopenia)
- 4Possible improvement in muscle function
- 5Research suggests metabolic benefits
- 6Effects on fat mass reduction
Claim vs Evidence
How popular claims about Follistatin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Builds muscle without steroids or HGH” | D | Limited | High | Animal-model evidence shows myostatin-inhibition muscle effects; human-outcomes evidence in healthy adults is limited and clinical use is research-only. |
| “Safe alternative to anabolic agents” | E | No | High | Prohibited under WADA S1.2 as an 'other anabolic agent'; safety profile in healthy adults is not established. |
| “Available as injection peptide from research suppliers” | E | No | High | Some 'follistatin' products on the grey market are mis-described or are gene-therapy constructs. Identity and purity unverified. |
| “Treats muscle-wasting conditions” | D | Limited | High | Clinical research is ongoing; no licensed UK follistatin medicine exists. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Not established for exogenous protein administration |
| Frequency | N/A |
| Duration | N/A |
| Notes | ⚠️ Follistatin is not approved for human performance enhancement. Gene therapy approaches are under clinical investigation for muscular dystrophies. Exogenous follistatin protein is challenging to administer effectively. Products sold as follistatin may have quality concerns. |
Administration Routes
Routes studied in research settings (educational only):
- Gene therapy (clinical trials for muscular dystrophy)
- Subcutaneous injection (research, with challenges)
| Half-Life | Stability |
|---|---|
| Variable by isoform; generally short for circulating protein | Complex glycoprotein requiring careful handling |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited human data for protein administration
- Gene therapy trials have generally been well tolerated
Rare Risks & Concerns
- Unknown long-term effects of sustained myostatin inhibition
- Theoretical concerns about tendon/ligament adaptation
- Potential effects on heart muscle (also expresses myostatin receptor)
- Reproductive effects possible (activin inhibition)
Contraindications
- Pregnancy (TGF-β family important for development)
- Cardiovascular disease (caution)
- Growing individuals (effects on growth plates unclear)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Research compound only.
🇪🇺 European Union
Not approved for any indication.
Clinical Studies Summary
Frequently Reported Blood Biomarkers in Sarcopenia Clinical Trials: A Systematic Review and Meta-Analysis.
There is an urgent need to adopt recommendations regarding muscle-specific BBMs to be assessed in sarcopenia RCTs. Developing a standardised Core Outcome Set for sarcopenia intervention studies would enhance the standardisation of sarcopenia RCTs and ultimately improve disease management.
Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.
Elevated circulating IGF-1 and, to a lesser extent, GDF-15, may be promising biomarkers for sarcopenia. Larger, longitudinal studies are needed to address heterogeneity and causality.
Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials.
Exercise training represents an anti-inflammatory therapy and metabolism-improving strategy with minimal side effects for patients with type 2 diabetes mellitus.
The effects of resistance training on myostatin and follistatin in adults: A systematic review and meta-analysis.
Resistance training in adults is effective for reducing myostatin and increasing follistatin which may contribute to the beneficial effects of resistance training on muscle mass and metabolic outcomes.
Synergistic Effects of Protein Intake and Exercise on Biomarkers of Sarcopenia: A Systematic Review.
Despite heterogeneity in duration and sample size, findings support this combined approach as a promising and clinically applicable strategy to prevent and treat sarcopenia. No external funding was received, and the review is registered in PROSPERO (CRD42025640989).
Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial.
A 12-week intervention combining resistance exercise and essential amino acid supplementation was superior to either intervention alone in enhancing muscle mass, muscle fitness, myokine profiles, and reducing inflammatory markers among healthy older women.
Registered Trials & Regulatory Status
7 of 7 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
Status: Recruiting · 12 participants · Unlimited Biotechnology LLC
Conditions: Age-related Muscle Decline
Stabilization vs Corrective Exercise in PFP
Status: Not Yet Recruiting · 60 participants · Ahram Canadian University
Conditions: Patellofemoral Pain Syndrome
HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
Status: Recruiting · 20 participants · Teachers College, Columbia University
Conditions: Spinal Muscular Atrophy (SMA)
Intrauterine Injection of Type III Collage in FST of EC/AEH
Status: Recruiting · 30 participants · Wang Jianliu
Conditions: Atypical Endometrial Hyperplasia, Endometrial Cancer
Safety and Efficacy of Klotho and Follistatin Gene Therapy
Status: Recruiting · 30 participants · Minicircle
Conditions: Healthy Adults
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
Status: Not Yet Recruiting · 12 participants · University Hospital, Clermont-Ferrand
Conditions: Cirrhosis With Hepatocellular Carcinoma
HABIT-ILE + FST in Children With SMA
Status: Active Not Recruiting · 5 participants · Teachers College, Columbia University
Conditions: SMA - Spinal Muscular Atrophy
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Status: Not Yet Recruiting · 10 participants · Peking University People's Hospital
Conditions: Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
Post Exercise Recovery and FST
Status: Not Yet Recruiting · 5 participants · University of British Columbia
Conditions: Exercise Therapy
The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis
Status: Unknown · 60 participants · Assiut University
Conditions: Multiple Sclerosis
Evaluation of Serum Follistatin-Like Protein 1 Levels in Behcet's Disease and Its Association With Disease Activity
Status: Completed · 80 participants · Assiut University
Conditions: Behcet Syndrome
Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Humans
Status: Completed · 43 participants · Minicircle
Conditions: Frailty, Aging
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Follistatin?
Source research-grade Follistatin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Follistatin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Follistatin a licensed UK medicine?
- Are there UK clinical trials for the muscle condition I'm asking about?
- What licensed treatments exist for muscle wasting in my situation?
- If I'm an athlete, what is the WADA position?
- If a clinic is offering 'follistatin', what is it actually selling — peptide or gene therapy?
UK regulatory & safety context
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreTB-500
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Learn moreIGF-1 LR3
A modified, highly potent analogue of insulin-like growth factor 1 with extended half-life and reduced binding protein affinity.
Learn more